A Long-Term Safety and Efficacy of SL77.0499-10 10mg Once-Daily Tablets in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia (BPH).A Multicenter, 52-Week, Open Label, Uncontrolled Study.

Trial Profile

A Long-Term Safety and Efficacy of SL77.0499-10 10mg Once-Daily Tablets in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia (BPH).A Multicenter, 52-Week, Open Label, Uncontrolled Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2009

At a glance

  • Drugs Alfuzosin (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Mar 2009 Actual patient number (148) added as reported by ClinicalTrials.gov.
    • 10 Mar 2009 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
    • 22 Jan 2008 Status changed from in progress to completed according to NCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top